Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

385
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
385
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

307
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
307
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

362
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
362

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Glucocorticoid-Induced Hyperglycaemia in Hospital: The Insulin Dose Matters Most.

Diabetes, obesity & metabolism·2026
Same author

A potentially dangerous case of mistaken identity: giant asymptomatic composite phaeochromocytoma.

Endocrinology, diabetes & metabolism case reports·2025
Same author

Performance of an individualized, subcutaneous, basal-bolus insulin regimen for the management of prednisolone-associated hyperglycemia in hospitalized patients: a proof-of-concept study.

BMJ open diabetes research & care·2025
Same author

Safe Continuation of Pegvisomant During Pregnancy in a Patient With Fibrous Dysplasia/McCune-Albright Syndrome.

JCEM case reports·2025
Same author

Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia: secondary analysis of a randomized controlled trial.

BMJ open diabetes research & care·2025
Same author

Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes.

Internal medicine journal·2024

関連する実験動画

Updated: Sep 10, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.3K

グルココルチコイドを止めるための実践的指針

Faran Khalili1,2, Morton G Burt1,2

  • 1Southern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Adelaide.

Australian prescriber
|August 27, 2025
PubMed
まとめ
この要約は機械生成です。

短期的に使用するグルココルチコイドは,突然中止することができます. 長時間使用すると,腎上腺不全を予防するために徐々に減量する必要があります.

キーワード:
HPA軸腎臓機能不全薬剤の縮小グルココルチコイド離脱症候群グルココルチコイド

さらに関連する動画

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.0K

関連する実験動画

Last Updated: Sep 10, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.3K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.0K

科学分野:

  • 内分泌学
  • 薬理学について

背景:

  • グルココルチコイドは一般的に処方される薬です.
  • 短期的な使用 (3~4週間未満) では,通常は投与量を徐々に減らす必要はありません.
  • 長期使用は下垂体- 垂体- 副腎 (HPA) 軸の抑制につながる可能性があります.

研究 の 目的:

  • グルココルチコイド停止の管理を概説する.
  • 徐々に減量する基準と突然停止する基準を特定する.
  • HPA軸の回復を評価する方法を記述する.

主な方法:

  • グルココルチコイド離脱に関する文献のレビュー
  • HPA軸の評価のための臨床ガイドライン
  • 様々な禁煙プロトコルを示すケーススタディ

主要な成果:

  • 短期間のグルココルチコイド使用では,突然の停止は安全です.
  • 長時間使用すると,腎上腺不全を避けるために徐々に減量する必要があります.
  • 朝の血清コルチゾール検査は,一部の患者に禁煙を導くことができます.
  • 持続的なHPA軸機能不全については,アドレノコルチオトロフィックホルモン刺激検査が必要になる場合があります.

結論:

  • グルココルチコイド治療の期間は,中止戦略を決定する.
  • HPA軸の評価は,長期使用後の安全なグルココルチコイド離脱に不可欠です.
  • 患者の個別化によるモニタリングと検査は 最適な結果を保証します